Article

Efficacy of BCG in bladder cancer may be predicted by cytokine response

Bacillus Calmette-Guérin (has been the standard of care for bladder cancer for nearly 40 years. Little is known about BCG or its mechanism of action, however. A trial currently under way at M.D. Anderson Cancer Center, Houston, may help urologists to separate responders from nonresponders early and tailor therapy for optimal results in those who respond to the drug.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Videos
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.